NAV

4-[3-carboxymethyl-3-(4-phosphonooxy-benzyl)-ureido]-4-[(3-cyclohexyl-propyl)-methyl-carbamoyl]butyric acid

Identification

Generic Name
4-[3-carboxymethyl-3-(4-phosphonooxy-benzyl)-ureido]-4-[(3-cyclohexyl-propyl)-methyl-carbamoyl]butyric acid
DrugBank Accession Number
DB01773
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Similar Structures
Weight
Average: 571.5571
Monoisotopic: 571.229480963
Chemical Formula
C25H38N3O10P
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UTyrosine-protein kinase transforming protein SrcNot AvailableRSV-SR-E
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Glutamic acid and derivatives
Alternative Parents
N-carbamoyl-alpha amino acids and derivatives / Alpha amino acid amides / Phenyl phosphates / Phenoxy compounds / N-acyl amines / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amides / Ureas / Carboxylic acids / Organopnictogen compounds
show 4 more
Substituents
Alpha-amino acid amide / Aromatic homomonocyclic compound / Aryl phosphate / Aryl phosphomonoester / Benzenoid / Carbonic acid derivative / Carbonyl group / Carboxamide group / Carboxylic acid / Dicarboxylic acid or derivatives
show 17 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
JSBQUMXQEBZYPW-NRFANRHFSA-N
InChI
InChI=1S/C25H38N3O10P/c1-27(15-5-8-18-6-3-2-4-7-18)24(33)21(13-14-22(29)30)26-25(34)28(17-23(31)32)16-19-9-11-20(12-10-19)38-39(35,36)37/h9-12,18,21H,2-8,13-17H2,1H3,(H,26,34)(H,29,30)(H,31,32)(H2,35,36,37)/t21-/m0/s1
IUPAC Name
(4S)-4-{[(carboxymethyl)({[4-(phosphonooxy)phenyl]methyl})carbamoyl]amino}-4-[(3-cyclohexylpropyl)(methyl)carbamoyl]butanoic acid
SMILES
CN(CCCC1CCCCC1)C(=O)[C@H](CCC(O)=O)NC(=O)N(CC(O)=O)CC1=CC=C(OP(O)(O)=O)C=C1

References

General References
Not Available
PubChem Compound
448585
PubChem Substance
46504571
ChemSpider
395343
BindingDB
50060737
ChEMBL
CHEMBL420910
ZINC
ZINC000014880066
PDBe Ligand
UR2
PDB Entries
1skj

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00321 mg/mLALOGPS
logP1.86ALOGPS
logP1.81Chemaxon
logS-5.2ALOGPS
pKa (Strongest Acidic)1.78Chemaxon
pKa (Strongest Basic)-2.5Chemaxon
Physiological Charge-4Chemaxon
Hydrogen Acceptor Count9Chemaxon
Hydrogen Donor Count5Chemaxon
Polar Surface Area194.01 Å2Chemaxon
Rotatable Bond Count15Chemaxon
Refractivity139.39 m3·mol-1Chemaxon
Polarizability57.06 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9295
Blood Brain Barrier+0.5588
Caco-2 permeable-0.6799
P-glycoprotein substrateSubstrate0.8715
P-glycoprotein inhibitor INon-inhibitor0.5466
P-glycoprotein inhibitor IINon-inhibitor0.9544
Renal organic cation transporterNon-inhibitor0.7983
CYP450 2C9 substrateNon-substrate0.612
CYP450 2D6 substrateNon-substrate0.8062
CYP450 3A4 substrateSubstrate0.5566
CYP450 1A2 substrateNon-inhibitor0.8624
CYP450 2C9 inhibitorNon-inhibitor0.668
CYP450 2D6 inhibitorNon-inhibitor0.8409
CYP450 2C19 inhibitorNon-inhibitor0.7008
CYP450 3A4 inhibitorInhibitor0.5646
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8128
Ames testNon AMES toxic0.6572
CarcinogenicityNon-carcinogens0.8464
BiodegradationNot ready biodegradable0.9304
Rat acute toxicity2.4811 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6535
hERG inhibition (predictor II)Inhibitor0.5304
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0120290000-95628fd5150c9cd8f807
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9010030000-10c5d5f514b9a48d9dd6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-056r-9030440000-f03a68a64cc7463addb2
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ufr-1940070000-f524d51e9b1a63f9711d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9451400000-db19fdb8f238e9feb052
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00or-1972370000-10085e8b544265000d31
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-222.17043
predicted
DeepCCS 1.0 (2019)
[M+H]+224.13979
predicted
DeepCCS 1.0 (2019)
[M+Na]+230.17548
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Tyrosine-protein kinase transforming protein Src
Kind
Protein
Organism
RSV-SR-E
Pharmacological action
Unknown
General Function
Non-membrane spanning protein tyrosine kinase activity
Specific Function
This phosphoprotein, required for both the initiation and the maintenance of neoplastic transformation, is a protein kinase that catalyzes the phosphorylation of tyrosine residues in vitro.
Gene Name
V-SRC
Uniprot ID
P63185
Uniprot Name
Tyrosine-protein kinase transforming protein Src
Molecular Weight
58952.655 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52